Published: Jan. 19, 2022 at 8:09 a.m. ET

By Chris Wack

Immix Biopharma Inc. said it saw positive interim clinical trial safety data demonstrating 100% completion of IMX-110 planned treatment cycles in its ongoing Phase 1b/2a clinical trial.

The company said that historically, 43% to 67% of patients have completed planned treatment cycles with approved drugs used to treat soft tissue sarcoma.

The U.S. Food and Drug Administration has approved orphan drug designation for IMX-110 for the treatment of soft tissue sarcoma. The FDA has already approved rare pediatric disease designation to IMX-110 for the treatment of a life-threatening pediatric cancer in children, rhabdomyosarcoma.

ImmixBio shares were up 10% to $6.40 in premarket trading.

Write to Chris Wack at

Original Article Link